pncA Large Deletion is the Characteristic of Pyrazinamide-Resistant Mycobacterium tuberculosis belonging to the East Asian Lineage
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Pyrazinamide (PZA) is often used as an add-on agent in the treatment of multidrug-resistant tuberculosis, regardless of phenotypic drug susceptibility testing (pDST) results. However, evaluating the effectiveness of PZA is challenging because of its low pH activity, which can result in unreliable pDST results. This study aimed to investigate the genomic characteristics associated with PZA resistance that can be used to develop genotypic DST. Materials and Methods: A publicly available whole genome sequencing (WGS) dataset of 10,725 Mycobacterium tuberculosis complex genomes (3,326 phenotypically PZA-resistant and 7,399 phenotypically PZA-susceptible isolates) were analyzed. Results: In total, 2,934 pncA non-silent mutations were identified in 2,880 isolates (26.9%). Detected mutations were found throughout the entire coding region of pncA in a scattered pattern, of which the most frequent mutation was p.Q10P (n = 278), followed by p.H57D (n = 167) and c.-11A>G (n = 122). The sensitivity and specificity of the group 1 or 2 mutations reported by the World Health Organization (WHO) mutational catalogue were 73.0% and 98.9%, respectively. We further identified 18 novel pncA mutations that were significantly associated with phenotypically PZA-resistant. In addition to these mutations, we identified 102 large deletions in the pncA gene, and all but two isolates were phenotypically resistant to PZA isolates. Notably, pncA deletions were mutually exclusive to pncA mutations, and more than half of the isolates with pncA large deletions belonged to the East Asian lineage (67.6%). The sensitivity, specificity, positive predictive value, and negative predictive value of the pooled variants (group 1 or 2 mutations, novel resistance-associated mutations, and large deletions of the pncA gene) were 79.0%, 98.9%, 97.0%, and 91.3%, respectively. The area under the curve (AUC) value for the pooled variants was significantly higher than the AUC value for the group 1 or 2 mutations (P <0.001), indicating that the pooled variants have a better discriminative ability for predicting PZA resistance. Conclusion: Using WGS, we found that the pncA mutations are scattered without specific mutational hotspots, and large deletions associated with PZA resistance are more common in the East Asian lineage of M. tuberculosis isolates. Our data also demonstrated the reliability of group 1 or 2 mutations presented in the WHO mutation catalogue and the need for further investigation on group 3 mutations, contributing to the evaluation of the current knowledge base on mutations associated with the PZA-resistant M. tuberculosis complex.
Abstract
Background: Pyrazinamide (PZA) is often used as an add-on agent in the treatment of multidrug-resistant tuberculosis, regardless of phenotypic drug susceptibility testing (pDST) results. However, evaluating the effectiveness of PZA is challenging because of its low pH activity, which can result in unreliable pDST results. This study aimed to investigate the genomic characteristics associated with PZA resistance that can be used to develop genotypic DST. Materials and Methods: A publicly available whole genome sequencing (WGS) dataset of 10,725 Mycobacterium tuberculosis complex genomes (3,326 phenotypically PZA-resistant and 7,399 phenotypically PZA-susceptible isolates) were analyzed. Results: In total, 2,934 pncA non-silent mutations were identified in 2,880 isolates (26.9%). Detected mutations were found throughout the entire coding region of pncA in a scattered pattern, of which the most frequent mutation was p.Q10P (n = 278), followed by p.H57D (n = 167) and c.-11A>G (n = 122). The sensitivity and specificity of the group 1 or 2 mutations reported by the World Health Organization (WHO) mutational catalogue were 73.0% and 98.9%, respectively. We further identified 18 novel pncA mutations that were significantly associated with phenotypically PZA-resistant. In addition to these mutations, we identified 102 large deletions in the pncA gene, and all but two isolates were phenotypically resistant to PZA isolates. Notably, pncA deletions were mutually exclusive to pncA mutations, and more than half of the isolates with pncA large deletions belonged to the East Asian lineage (67.6%). The sensitivity, specificity, positive predictive value, and negative predictive value of the pooled variants (group 1 or 2 mutations, novel resistance-associated mutations, and large deletions of the pncA gene) were 79.0%, 98.9%, 97.0%, and 91.3%, respectively. The area under the curve (AUC) value for the pooled variants was significantly higher than the AUC value for the group 1 or 2 mutations (P <0.001), indicating that the pooled variants have a better discriminative ability for predicting PZA resistance. Conclusion: Using WGS, we found that the pncA mutations are scattered without specific mutational hotspots, and large deletions associated with PZA resistance are more common in the East Asian lineage of M. tuberculosis isolates. Our data also demonstrated the reliability of group 1 or 2 mutations presented in the WHO mutation catalogue and the need for further investigation on group 3 mutations, contributing to the evaluation of the current knowledge base on mutations associated with the PZA-resistant M. tuberculosis complex.
참고문헌 (34)
- 송재훈, "Modern History of Tuberculosis in Korea", Infection and Chemotherapy, 51(4), pp.414~426 (2019), 대한감염학회[DOI]
- Lee Chan Mi, "Prevalence of Multidrug-Resistant Tuberculosis in HIV", Tuberculosis Co-Infected Patients, 2021, pp.53(4), 792~795[DOI]
- Kim J, "Characteristics of the notified tuberculosis – the Republic of Korea, 2021", Public Health Weekly Report, 15, pp.739~746 (2022)
- Martinez E, "Genome sequencing reveals novel deletions associated with secondary resistance to pyrazinamide in MDR Mycobacterium tuberculosis", J Antimicrob Chemother, 70, pp.2511~2514 (2015)
- World Health Organization(WHO), "WHO treatment guidelines for isoniazid-resistant tuberculosis: supplement to the WHO treatment guidelines for drug-resistant tuberculosis", WHO, ~ (2018)
- World Health Organization(WHO), "Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis", WHO, ~ (2018)
- Mok S, "Overcoming the challenges of pyrazinamide susceptibility testing in clinical Mycobacterium tuberculosis isolates", Antimicrob Agents Chemother, 65, pp.e0261720~ (2021)
- Köser CU, "Whole-genome sequencing for rapid susceptibility testing of M. tuberculosis", N Engl J Med, 369, pp.290~292 (2013)
- CRyPTIC Consortium and the 100,000 Genomes Project, "Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing", N Engl J Med, 379, pp.1403~1415 (2018)
- Walker TM, "Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance : a retrospective cohort study", Lancet Infect Dis, 15, pp.1193~1202 (2015)
- Walker TM, "The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance : a genotypic analysis", Lancet Microbe, 3, pp.e265~73 (2022)
- Ramaswamy SV, "Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis", Antimicrob Agents Chemother, 47, pp.1241~1250 (2003)
- Suzuki Y, "Rapid detection of pyrazinamide-resistant Mycobacterium tuberculosis by a PCR-based in vitro system", J Clin Microbiol, 40, pp.501~507 (2002)
- Huang H, "Cross-sectional whole-genome sequencing and epidemiological study of multidrug-resistant Mycobacterium tuberculosis in China", Clin Infect Dis, 69, pp.405~413 (2019)
- Merker M, "Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage", Nat Genet, 47, pp.242~249 (2015)
- Andres S, "A diagnostic algorithm to investigate pyrazinamide and ethambutol resistance in rifampin-resistant Mycobacterium tuberculosis isolates in a low-incidence setting", Antimicrob Agents Chemother, 63, pp.e01798-18~ (2019)
- van Beek J, "Evaluation of whole genome sequencing and software tools for drug susceptibility testing of Mycobacterium tuberculosis", Clin Microbiol Infect, 25, pp.82~86 (2019)
- Yang C, "Transmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai, China : a retrospective observational study using whole-genome sequencing and epidemiological investigation", Lancet Infect Dis, 17, pp.275~284 (2017)
- Coll F, "Genome-wide analysis of multi-and extensively drug-resistant Mycobacterium tuberculosis", Nat Genet, 50, pp.307~316 (2018)
- Cohen KA, "Evolution of extensively drug-resistant tuberculosis over four decades : whole genome sequencing and dating analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal", PLoS Med, 12, pp.e1001880~ (2015)
- Clark TG, "Elucidating emergence and transmission of multidrug-resistant tuberculosis in treatment experienced patients by whole genome sequencing", PLoS One, 8, pp.e83012~ (2013)
- Gomes LC, "Whole genome sequencing reveals large deletions and other loss of function mutations in Mycobacterium tuberculosis drug resistance genes", Microb Genom, 7, pp.000724~ (2021)
- Pankhurst LJ, "Rapid, comprehensive, and affordable mycobacterial diagnosis with whole-genome sequencing : a prospective study", Lancet Respir Med, 4, pp.49~58 (2016)
- Billard-Pomares T, "Use of whole-genome sequencing to explore Mycobacterium tuberculosis complex circulating in a hotspot department in France", Microorganisms, 10, pp.1586~ (2022)
- Casali N, "Evolution and transmission of drug-resistant tuberculosis in a Russian population", Nat Genet, 46, pp.279~286 (2014)
- Casali N, "Microevolution of extensively drug-resistant tuberculosis in Russia", Genome Res, 22, pp.735~745 (2012)
- Feuerriegel S, "PhyResSE : a web tool delineating Mycobacterium tuberculosis antibiotic resistance and lneage from whole-genome sequencing data", J Clin Microbiol, 53, pp.1908~1914 (2015)
- Brown AC, "Rapid whole-genome sequencing of Mycobacterium tuberculosis isolates directly from clinical samples", J Clin Microbiol, 53, pp.2230~2237 (2015)
- Iwamoto T, "Overcoming the pitfalls of automatic interpretation of whole genome sequencing data by online tools for the prediction of pyrazinamide resistance in Mycobacterium tuberculosis", PLoS One, 14, pp.e0212798~ (2019)
- Jung SH, "Whole-exome sequencing identifies recurrent AKT1 mutations in sclerosing hemangioma of lung", Proc Natl Acad Sci U S A, 113, pp.10672~10677 (2016)
- Danecek P, "Twelve years of SAMtools and BCFtools", Gigascience, 10, pp.giab008~ (2021)
- Cingolani P, "A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff : SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3", Fly(Austin), 6, pp.80~92 (2012)
- Napier G, "Robust barcoding and identification of Mycobacterium tuberculosis lineages for epidemiological and clinical studies", Genome Med, 12, pp.114~ (2020)
- Rausch T, "DELLY : structural variant discovery by integrated paired-end and split-read analysis", Bioinformatics, 28, pp.i333~9 (2012)